NCT05237947 2026-03-19
PRISMA
National Cancer Institute (NCI)
Phase 4 Active not recruiting
Clinical Trials
48 trialsNCT07281677 2025-12-15
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
Zhejiang Provincial Center for Disease Control and Prevention
Phase 4 Recruiting
NCT02834637 2025-09-10
DoRIS
London School of Hygiene and Tropical Medicine
Phase 3 Active not recruiting
NCT03180034 2025-09-04
ESCUDDO
National Cancer Institute (NCI)
Phase 4 Active not recruiting
NCT03728881 2025-08-03
PRIMAVERA
National Cancer Institute (NCI)
Phase 3 Completed
NCT05291845 2025-06-12
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Zagazig University
Phase 2 Recruiting
NCT00481767 2020-11-17
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
GlaxoSmithKline
Phase 3 Completed
NCT00956553 2020-10-01
HPV CSP01
Public Health England
Phase 4 Completed
NCT03105856 2020-08-10
FASTER
Instituto Nacional de Salud Publica, Mexico
Phase 4 Completed
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT01381575 2020-06-09
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
GlaxoSmithKline
Phase 3 Completed
NCT01627561 2020-04-10
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
GlaxoSmithKline
Phase 3 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00637195 2020-01-03
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
GlaxoSmithKline
Phase 3 Completed
NCT00250276 2020-01-02
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
GlaxoSmithKline
Phase 3 Completed
NCT00294047 2020-01-02
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
GlaxoSmithKline
Phase 3 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00534638 2019-11-15
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
GlaxoSmithKline
Phase 4 Completed
NCT01462357 2019-11-15
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
GlaxoSmithKline
Phase 3 Completed
NCT01249365 2019-11-13
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
GlaxoSmithKline
Phase 3 Completed
NCT00730847 2019-11-05
A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
GlaxoSmithKline
Phase 4 Terminated
NCT01190176 2019-10-30
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01190189 2019-06-19
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
GlaxoSmithKline
Phase 3 Completed
NCT02837926 2019-04-10
CoheaHr-WP4
CHU de Reims
Phase 4 Completed
NCT00128661 2019-03-08
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
GlaxoSmithKline
Phase 3 Completed
NCT00309166 2018-09-17
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
GlaxoSmithKline
Phase 2 Completed
NCT00492544 2018-09-04
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00122681 2018-08-20
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
GlaxoSmithKline
Phase 3 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed
NCT00578227 2018-08-17
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01101542 2018-07-23
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
GlaxoSmithKline
Completed
NCT00344032 2018-07-20
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women
GlaxoSmithKline
Phase 3 Completed
NCT00485732 2018-07-20
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
GlaxoSmithKline
Phase 3 Completed
NCT00549900 2018-07-20
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
GlaxoSmithKline
Phase 1 Completed
NCT00799825 2018-07-12
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
GlaxoSmithKline
Phase 3 Completed
NCT00546078 2018-06-26
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
GlaxoSmithKline
Phase 2 Completed
NCT00337818 2017-05-30
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
GlaxoSmithKline
Phase 3 Completed
NCT00518336 2016-12-09
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
GlaxoSmithKline
Phase 2 Completed
NCT00811798 2016-10-20
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00689741 2016-09-12
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
GlaxoSmithKline
Phase 2 Completed
NCT02276521 2015-09-23
Evaluation of Long Term Immunity Following HPV Vaccination
Murdoch Childrens Research Institute
Completed
NCT02082639 2015-07-20
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
GlaxoSmithKline
Phase 3 Withdrawn
NCT02100618 2015-07-20
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
GlaxoSmithKline
Phase 3 Withdrawn
NCT01498627 2015-04-06
PGRx
GlaxoSmithKline
Completed
NCT01187927 2015-01-26
Drug Use Investigation for Cervarix®
GlaxoSmithKline
Completed
NCT01905462 2013-09-30
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
GlaxoSmithKline
Completed
NCT00316706 2012-09-18
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
GlaxoSmithKline
Phase 3 Completed
NCT01082861 2010-03-19
TANGO
National Institute for Public Health and the Environment (RIVM)
Phase 4 Terminated